A real-world study of the efficacy and safety of polymyxin-e sodium mesylate in the treatment of carbapenem-resistant Gram-negative bacilli infection

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100054085

Enrollment

Unknown

Registered

2021-12-08

Start date

2021-12-08

Completion date

Unknown

Last updated

2022-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Interventions

observation group:Colistimethate sodium

Eligibility

Sex/Gender

All

Age

14 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. ICU patients aged >=14 years; 2. Definite CRO infection; 3. Physicians evaluated patients requiring systemic antibiotic therapy in combination with Colistimethate sodium for 7 days or more due to clinical needs.

Exclusion criteria

Exclusion criteria: 1. Patients who received other polymyxins within 7 days before inclusion; 2. Known allergic to polymyxin E sodium methanesulfonate; 3. Positive pregnancy test or breastfeeding; 4. The investigator believes that there are other inappropriate inclusion factors.

Design outcomes

Primary

Measure	Time frame
Clinical improvement rate;All-cause mortality rate;Incidence of adverse reactions;	—

Countries

China

Contacts

Public ContactShao Huanzhang

Henan Provincial People's Hospital

shaohuanzhang@sina.com+86 18535297681

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026